Summary
Cipla anticipates a ramp-up in US sales by FY27 and maintains its full-year Ebitda margin guidance of 18.5-20%, with plans to launch key new products.
Cipla Expects US Sales Ramp-Up by FY27, Maintains Full-Year Guidance
HyperFast News
Related news
Maharashtra FDA withdraws Cipla Pharma license cancellation order after Bombay HC criticism
19 Sept 2026, 2:50 pm · News
Maharashtra FDA Cancels Cipla Unit's Drug Licence for Reactin Plus Irregularities
19 Sept 2026, 2:50 pm · News
Cipla Gets U.S. FDA Approval for Generic Asthma, COPD Drug
19 Sept 2026, 2:50 pm · News
